Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

CELSA, Ciro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.999
EU - Europa 2.874
AS - Asia 2.845
SA - Sud America 501
AF - Africa 81
OC - Oceania 9
Totale 10.309
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.891
RU - Federazione Russa 1.086
SG - Singapore 1.051
IT - Italia 654
CN - Cina 585
BR - Brasile 387
HK - Hong Kong 317
VN - Vietnam 307
DE - Germania 263
PL - Polonia 220
BD - Bangladesh 177
FR - Francia 157
FI - Finlandia 130
GB - Regno Unito 104
JP - Giappone 102
IN - India 63
CA - Canada 58
AT - Austria 44
AR - Argentina 41
TR - Turchia 36
ES - Italia 35
IE - Irlanda 34
SE - Svezia 31
KR - Corea 30
MX - Messico 30
IQ - Iraq 29
NL - Olanda 27
EC - Ecuador 22
ZA - Sudafrica 20
VE - Venezuela 17
CI - Costa d'Avorio 16
UZ - Uzbekistan 15
PK - Pakistan 14
PY - Paraguay 14
RO - Romania 14
SA - Arabia Saudita 14
BE - Belgio 12
MY - Malesia 12
UA - Ucraina 12
EG - Egitto 11
ID - Indonesia 11
PH - Filippine 11
LT - Lituania 10
MA - Marocco 9
AE - Emirati Arabi Uniti 8
AU - Australia 8
DZ - Algeria 8
CH - Svizzera 7
CO - Colombia 7
JO - Giordania 7
KZ - Kazakistan 7
CL - Cile 6
IL - Israele 6
TN - Tunisia 6
AL - Albania 5
AZ - Azerbaigian 5
GE - Georgia 5
JM - Giamaica 5
NP - Nepal 5
CZ - Repubblica Ceca 4
KE - Kenya 4
OM - Oman 4
PS - Palestinian Territory 4
RS - Serbia 4
TH - Thailandia 4
TW - Taiwan 4
BS - Bahamas 3
HU - Ungheria 3
NO - Norvegia 3
PT - Portogallo 3
UY - Uruguay 3
CR - Costa Rica 2
GR - Grecia 2
GT - Guatemala 2
GY - Guiana 2
HN - Honduras 2
LB - Libano 2
LV - Lettonia 2
NG - Nigeria 2
NI - Nicaragua 2
PE - Perù 2
QA - Qatar 2
SN - Senegal 2
TT - Trinidad e Tobago 2
AF - Afghanistan, Repubblica islamica di 1
BG - Bulgaria 1
BY - Bielorussia 1
CY - Cipro 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GA - Gabon 1
HR - Croazia 1
IR - Iran 1
KG - Kirghizistan 1
LK - Sri Lanka 1
MG - Madagascar 1
MM - Myanmar 1
MN - Mongolia 1
MT - Malta 1
Totale 10.303
Salva come PNG Salva come JPEG
Città #
Singapore 696
Ashburn 645
San Jose 399
Hong Kong 297
Chandler 277
Fairfield 212
Zgierz 192
Moscow 171
New York 151
Palermo 143
Council Bluffs 124
Los Angeles 114
Ho Chi Minh City 108
Beijing 103
Lauterbourg 97
Tokyo 94
Hefei 84
Woodbridge 83
Houston 82
Helsinki 81
Santa Clara 76
Seattle 69
Ann Arbor 68
Wilmington 68
Hanoi 67
The Dalles 67
Rome 64
Altamura 63
Medford 58
Dallas 57
Cambridge 45
Frankfurt am Main 43
Lappeenranta 43
Orem 41
Milan 39
Lawrence 36
Princeton 36
Buffalo 35
Nuremberg 35
Dublin 34
São Paulo 32
London 30
Ludwigshafen am Rhein 28
Bremen 27
Des Moines 26
Warsaw 25
Chicago 24
Vienna 22
Montreal 21
San Diego 21
Brooklyn 18
Denver 18
Chennai 17
Da Nang 17
Abidjan 16
Atlanta 16
Poplar 15
Columbus 14
Johannesburg 14
Tashkent 14
Ankara 13
Haiphong 13
Phoenix 13
Redondo Beach 13
Stockholm 13
West Jordan 12
Biên Hòa 11
Bologna 11
Florence 11
Amsterdam 10
Belo Horizonte 10
Dhaka 10
Guangzhou 10
Rio de Janeiro 10
Baghdad 9
Boardman 9
Central 9
Hải Dương 9
Mexico City 9
Naples 9
Paris 9
Porto Alegre 9
Quito 9
Toronto 9
Washington 9
Brasília 8
Brussels 8
Cordova 8
Falkenstein 8
Gangbuk-gu 8
Istanbul 8
Krefeld 8
Munich 8
Pune 8
Salt Lake City 8
San Francisco 8
Tianjin 8
Venice 8
Changsha 7
Hillsboro 7
Totale 5.989
Salva come PNG Salva come JPEG
Nome #
Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients with Non-alcoholic Fatty Liver Disease 295
Antidiabetic drugs in NAFLD: The accomplishment of two goals at once? 259
Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 244
Optimizing sequential systemic therapies for advanced hepatocellular carcinoma: A decision analysis 202
Risk Factors for Rate of Relapse and Effects of Steroid Maintenance Therapy in Patients With Autoimmune Pancreatitis: Systematic Review and Meta-analysis 194
Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 193
Pharmacological therapy of non-alcoholic fatty liver disease: What drugs are available now and future perspectives 190
Predicting in-hospital mortality from Coronavirus Disease 2019: A simple validated app for clinical use 190
Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma 188
The burden of hepatocellular carcinoma in non-alcoholic fatty liver disease: Screening issue and future perspectives 179
Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization? 172
Diagnostic performance of endoscopic ultrasound through-the-needle microforceps biopsy of pancreatic cystic lesions: Systematic review with meta-analysis 168
Systemic therapies for hepatocellular carcinoma: The present and the future 164
Telemedicine Is an Effective Tool to Monitor Disease Activity in IBD Patients in the COVID-19 Era: A Single Centre Experience Based on Objective Data 163
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 158
AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD 157
Biochemical biomarkers of NAFLD/NASH 156
Direct-acting antiviral agents and risk of Hepatocellular carcinoma: Critical appraisal of the evidence 153
Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: A validated prediction model 151
Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis 150
Competing-risk analysis of coronavirus disease 2019 in-hospital mortality in a Northern Italian centre from SMAtteo COvid19 REgistry (SMACORE) 144
Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis 143
The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints 139
Long-term evolution of LI-RADS observations in HCV-related cirrhosis treated with direct-acting antivirals 138
Impact of biliary stents on the diagnostic accuracy of EUS-guided fine-needle biopsy of solid pancreatic head lesions: A multicenter study 138
First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials 131
Clinical outcomes of MAFLD versus NAFLD: A meta-analysis of observational studies 129
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: An individual patient data meta-analysis 129
RESIST-HCV Criteria to Monitor Progression of Low-Risk Esophageal Varices in Patients With Compensated Cirrhosis After HCV Eradication: The SIMPLE Study: SIMPLE: Scoring Index to Monitor Progression of Low-risk Esophageal varices 127
Consequences of Extended Spectrum Beta-Lactamase–Producing Enterobacteriaceae and Methicillin-Resistant Staphylococcus aureus Carriage in Awaiting Liver Transplant Patients 127
Radiomics Analysis on Gadoxetate Disodium-Enhanced MRI Predicts Response to Transarterial Embolization in Patients with HCC 125
Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19 125
Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies 124
Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study 124
Biliary complications after liver transplantation: current perspectives and future strategies 123
Direct-acting antiviral agents and risk of hepatocellular carcinoma: is it still a clinical dilemma? 122
What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg-negative anti-HBc-positive patients? Meta-analysis and decision curve analysis 121
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 118
Minimally invasive hepatectomy vs. thermoablation for single small (≤3 cm) hepatocellular carcinoma: A weighted real-life national comparison 116
Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis 112
Efficacy of lumen-apposing metal stents or self-expandable metal stents for endoscopic ultrasound-guided choledochoduodenostomy: A systematic review and meta-analysis 112
Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death 108
Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib 108
Reply 107
Hepatic encephalopathy increases the risk for mortality and hospital readmission in decompensated cirrhotic patients: a prospective multicenter study 107
A Markov Model Unveiling the Impact of Resmetirom on the Natural History of MASLD Patients: A Sistematic Review and Meta-Analysis 104
Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment 100
Non-Invasive Diagnostic Tests for Portal Hypertension in Patients with HBV- and HCV-Related Cirrhosis: A Comprehensive Review 98
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours 98
Reply 98
Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer? 98
Role of LI-RADS Indeterminate Observations in the Risk of Hepatocellular Carcinoma after HCV Eradication with Direct-Acting Antivirals 97
Initial uptake of durvalumab with or without tremelimumab for advanced hepatocellular carcinoma in routine clinical practice: Preliminary results of the international DT-real study 97
Outcomes of hepatocellular carcinoma patients treated with sorafenib: A meta-analysis of Phase III trials 97
Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial 95
Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma: A Real-life Multicentric Weighted Comparison 95
The Application of Large Language Models in Gastroenterology: A Review of the Literature 90
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study 87
Textbook Outcome After Trans-arterial Chemoembolization for Hepatocellular Carcinoma 87
Surveillance as determinant of long-term survival in non-transplanted hepatocellular carcinoma patients 86
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis 85
Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study 84
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma 84
COSMIC-312: mounting immunotherapy enigmas for hepatocellular carcinoma 84
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib 84
Hepatocellular carcinoma in people living with HIV 82
Identification of clinical phenotypes and related survival in patients with large hccs 82
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence 81
Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma 80
Sicily Network for Liver Cancer: A Multidisciplinary Network Model for the Management of Primary Liver Tumors 78
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction 77
Through-the-needle biopsy of pancreatic cystic lesions: stronger evidences of higher diagnostic yield compared with cytology 76
Navigating the landscape of liver cancer management: Study designs in clinical trials and clinical practice 75
Hepatitis C Eradication Improves Oncologic and Clinical Outcomes in Patients Treated With Atezolizumab Plus Bevacizumab 72
Risk profiling of hepatocellular carcinoma occurrence after eradication of hepatitis C virus with direct-acting antiviral agents 71
The application of artificial intelligence-based tools in the management of hepatocellular carcinoma: current status and future perspectives 71
Establishing hepatic decompensation as a meaningful clinical outcome during systemic therapy for hepatocellular carcinoma 69
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab 68
Reliability of grading preoperative pancreatic neuroendocrine tumors on EUS specimens: a systematic review with meta-analysis of aggregate and individual data 68
The price and value of therapeutic synergy in liver cancer 68
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib 67
The relevance of noninvasive tools to assess fibrosis in non-alcoholic fatty liver disease 65
354P A multimodal deep learning model for prediction of early progression in patients with advanced hepatocellular carcinoma treated with atezolizumab-bevacizumab 63
Noninvasive Assessment of Portal Hypertension in Patients With Primary Biliary Cholangitis Is Affected by Severity of Cholestasis 61
Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study 61
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept 59
Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moon 56
Patients’ radiation exposure during TIPS creation in a high-volume referral hospital 55
Endothelial angiopoietin-2 overexpression in explanted livers identifies subjects at higher risk of recurrence of hepatocellular carcinoma after liver transplantation 53
Evaluating the predictive performance of the elderly patient calculator TIPS score in a North American cohort 51
Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma 50
Reply to: “irLI or not irLI: That is the question” 50
Expert opinion vs. meta-analysis: To be or not to be? 48
Characteristics and Outcomes of Hepatocellular Carcinoma in Patients with Autoimmune Hepatitis 47
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs 47
Recurrence rate, features, and outcome after hepatocellular carcinoma curative resection or ablation according to the IMbrave050 criteria: a real-world study 40
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab 39
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab 37
Unmet needs in hepatology: The guidance of the Italian association for the study of the liver (AISF) 36
Reply: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 35
Totale 10.809
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.521
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.521
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202135 0 0 0 0 0 0 0 0 0 0 0 35
2021/2022534 50 36 16 17 5 14 10 158 70 32 32 94
2022/2023923 60 165 8 112 82 103 89 73 159 10 35 27
2023/2024550 24 54 36 43 19 153 59 17 17 29 32 67
2024/20251.768 35 125 217 131 31 140 146 82 96 193 229 343
2025/20266.499 417 165 393 679 611 991 858 850 561 461 503 10
Totale 10.954